Bluebird Bio
Bluebird Bio Sold to Private Investment Firms Amid Financial Challenges
Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.
The FDA approved three new gene therapy products in 2024 and expanded indications for two others, all for rare diseases.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on investigational candidates.
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have none after treatment.
Vertex Pharmaceuticals, Bluebird Bio to Participate in CMS Cell and Gene Therapy Access Model
CMS has negotiated outcomes-based agreements for sickle cell gene therapies with the two companies on behalf of participating state Medicaid programs.
Mar 18, 2024
Bluebird Bio Enters Into $175M Loan Deal
Dec 29, 2023